The findings suggest that MM07 could be used to replace decreasing levels of endogenous apelin peptide observed in PAH, and could be employed as a potential adjuvant therapy in patients who do not respond sufficiently to standard-of-care treatment options. This evidence concerns the gene APLN and pulmonary arterial hypertension.